دورية أكاديمية

988P Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC

التفاصيل البيبلوغرافية
العنوان: 988P Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC
المؤلفون: Vogel, A., Müller, D.W., De Toni, E., Siegler, G.M., Siebler, J., Lindig, U., Müller, T., Schultheiss, M., Geißler, M., Krammer-Steiner, B., Reichart, A., Lammert, F., Prause, C., Walker, M., Al-Batran, S-E., Kosic, N.
المصدر: In Annals of Oncology September 2020 31 Supplement 4:S691-S691
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1016/j.annonc.2020.08.1104